Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Deferred Taxes: 2013-2023

Historic Deferred Taxes for Lineage Cell Therapeutics (LCTX) over the last 5 years, with Dec 2023 value amounting to -$1.8 million.

  • Lineage Cell Therapeutics' Deferred Taxes was N/A to -$1.8 million in Q1 2023 from the same period last year, while for Mar 2023 it was -$4.1 million, marking a year-over-year change of. This contributed to the annual value of -$1.8 million for FY2023, which is N/A change from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Deferred Taxes stood at -$1.8 million for FY2023, which was down 45.52% from -$1.2 million recorded in FY2020.
  • Lineage Cell Therapeutics' 5-year Deferred Taxes high stood at -$1.2 million for FY2020, and its period low was -$1.8 million during FY2023.
  • Its 1-year average for Deferred Taxes is -$1.8 million, with a median of -$1.8 million in 2023.